The significance of CGRP in migraine has been extensively established, particularly evident in the success of eight FDA-approved CGRP-based therapeutics (four anti-CGRP monoclonal antibodies—‘mAbs’ and four CGRP receptor small-molecule inhibitors—‘Gepants’). The gene discussed is CALCA; the disease is migraine disorder.